Gastrointestinal Cancer | Specialty

Dovitinib Meets Primary Endpoint in Phase II Trial of Advanced GIST

September 27th 2014

Dovitinib, an investigational oral tyrosine kinase inhibitor (TKI), demonstrated a "manageable" safety profile while controlling disease in about half of patients with advanced gastrointestinal stromal tumor (GIST) who had discontinued treatment with imatinib due to disease progression or intolerance

Dr. Mehta Discusses the Reliability of Automated Segmentation for Lung Volumes in Multiple Cancers

September 23rd 2014

Niraj Mehta, MD, Radiation Oncologist, 21st Century Oncology, discusses the reliability of automated segmentation for lung volumes in breast, lung, and esophageal cancers.

Blood-Based Biomarkers Predict Outcomes Following Neoadjuvant Treatment in Esophageal Cancer

September 16th 2014

High pretreatment levels of serum VEGF-A and TGF-β1 indicated significantly worse disease-free survival (DFS) following neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Potentially Curative Surgery Achievable With Chemo/SABR Combination for Advanced Pancreatic Cancer

September 16th 2014

The combination of chemotherapy and stereotactic ablative radiotherapy (SABR) may allow patients with locally advanced pancreatic cancer to undergo surgery, a procedure that might not have otherwise been an option

Radiotherapy Without Chemo Can Ease Dysphagia in Patients With Advanced Esophageal Cancer

September 15th 2014

Radiotherapy is equally as effective in the palliation of dysphagia (difficulty swallowing) as chemoradiotherapy for patients with advanced esophageal cancer

Dr. Venook Discusses the Future of Colorectal Cancer Treatment

September 15th 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the future of colorectal cancer treatment.

Ramucirumab Improves Survival in mCRC

September 12th 2014

The combination of ramucirumab and FOLFIRI significantly improved OS and PFS compared with chemotherapy alone as a second-line treatment for patients with mCRC.

Immunotherapy Combined With Chemotherapy for Pancreatic Cancer: A Game Changer?

September 5th 2014

This article reviews up-to-date clinical studies combining chemotherapy with immunotherapy; it also explains the rationale for this combination in treatment of pancreatic cancer.

Four Distinct Subtypes of Gastric Cancer Found

September 4th 2014

Gastric cancer is comprised of 4 distinct molecular subtypes of disease, each representing a unique opportunity for new drug development, according to a paper published in Nature by The Cancer Genome Atlas (TCGA).

FDA Grants Priority Review to Lanreotide for GEP NETs

September 3rd 2014

The FDA has assigned a priority review designation to lanreotide (Somatuline Depot) as a treatment for patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)

Dr. Arkenau Discusses AZD4547 and FGFR Amplification in Advanced Solid Tumors

August 28th 2014

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of AZD4547 in patients with advanced tumors.

BRAF-Mutated Colorectal Cancer: Early Frustrations and Future Optimism

August 22nd 2014

This review highlights that preclinical data and discusses several ongoing clinical trials that are leveraging this information to explore new therapeutic strategies in targeting BRAF-mutated colorectal cancer.

Dr. Peeters Discusses the Efficacy and Safety of Panitumumab Versus Cetuximab in CRC

August 19th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the efficacy and safety of panitumumab versus cetuximab as seen in the ASPECCT trial in colorectal cancer (CRC).

Dr. Venook Discusses the Results of the 80405 Trial

August 15th 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial of targeted therapies administered in colorectal cancer.

FDA Approves First DNA-Based CRC Screening Tool

August 12th 2014

The FDA has approved the noninvasive stool-based DNA test Cologuard for the detection of colorectal cancer or cancer precursors in asymptomatic patients at average risk.

Dr. Tempero Discusses Screening for Pancreatic Cancer

August 12th 2014

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses screening tools used for patients at high risk for pancreatic cancer.

The Pivotal Role of Cooperative Group Trials

August 8th 2014

Managing Toxicities Associated With Regorafenib

August 8th 2014

Case Studies in Advanced Colorectal Cancer

August 8th 2014

Optimal Dosing of Regorafenib in CRC

August 8th 2014